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320Partial T Cell-Depleted Allogeneic Stem Cell
Transplantation following Reduced-Intensity
Conditioning Creates a Platform for Immunotherapy
with Donor Lymphocyte Infusion and Recipient
Dendritic Cell Vaccination in Multiple Myeloma
Henrie¨tte Levenga,1 Nicolaas Schaap,1 Frans Maas,2 Bennie Esendam,2 Hanny Fredrix,2
Annelies Greupink-Draaisma,2 Theo de Witte,1 Harry Dolstra,2 Reinier Raymakers1Allogeneic stem cell transplantation (SCT) in multiple myeloma (MM) may induce a curative graft-versus-
myeloma (GVM) effect. Major drawback in unmanipulated reduced-intensity conditioning (RIC) SCT is the
risk of severe and longstanding graft-versus-host-disease (GVHD). This study demonstrates that transplan-
tation with a partial T cell-depleted graft creates a platform for boosting GVM immunity by preemptive donor
lymphocyte infusion (DLI) and recipient dendritic cell (DC) vaccination, with limited GVHD. All 20 MM
patients engrafted successfully. Chimerism analysis in 19 patients evaluable at 3 months revealed that
7 patients were complete donor, whereas 12 patients were mixed chimeric. Grade II acute GVHD (aGVHD)
occurred in 7 patients (35%) and only 4 patients (21%) developed chronic GVHD (cGVHD). Fourteen
patients received posttransplantation immunotherapy, 8 preemptive DLI, 5 patients both DLI and DC
vaccination, and 1 patient DC vaccination only. DC vaccination was associated with limited toxicity, and
none of these patients developed GVHD. Importantly, overall treatment-related mortality (TRM) at 1
year was low (10%). Moreover, the overall survival (OS) is 84% with median follow-up of 27 months, and
none of the patients died from progressive disease. These findings illustrate that this novel approach is asso-
ciated with limited GVHD and mortality, thus creating an ideal platform for adjuvant immunotherapy.
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Allogeneic stem cell transplantation (SCT) may
cure patients with multiple myeloma (MM) because
of a graft-versus-myeloma (GVM) effect. Myeloabla-
tive (MA) conditioning has been limited by a high
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6/j.bbmt.2009.10.006reduced-intensity conditioning SCT (RIC-SCT) fol-
lowing autologous SCT seems a promising approach.
Importantly, TRM following RIC-SCT is reduced
from 30% to 40% to 10% to 20% [1]. However, 3 pro-
spective trials comparing autologous transplantation
followed by RIC-SCT versus double autologous
SCT showed contradictory results in clinical outcome
[2-4]. The study by Bruno et al. [2] showed a superior
overall survival (OS) for autologous SCT followed by
allogeneic RIC-SCT. In line with this study, Rosin˜ol
et al. [4] observed a trend toward a longer progres-
sion-free survival (PFS) for patients treated with
auto/RIC-SCT, but no significant differences in
event-free survival (EFS) and OS. In contrast, the In-
tergroupe Francophone du Myelome (IFM) observed
no differences in EFS and OS comparing double au-
tologous SCT versus auto/RIC-SCT in high-risk pa-
tients. Although these differences in outcome may be
explained by different inclusion criteria and treatment
schedules, they illustrate that improvement of the
Biol Blood Marrow Transplant 16:320-332, 2010 321Reduced Intensity Conditioning SCT for MMGVM effect, without the toxicity and morbidity of
graft-versus-host disease (GVHD) after allogeneic
RIC-SCT, is a prerequisite to further establish this
therapeutic approach.
Previously, we showed that partial T cell-depleted
allogeneic SCT followed by preemptive donor lym-
phocyte infusion (DLI) resulted in long-term com-
plete remission (CR) in about one-third of MM
patients [5]. In this cohort of 24 patients, 1-year
TRM after MA conditioning was 29%. But a continu-
ous CR in 7 MM patients after preemptive DLI with
a median follow-up of 8.6 years encouraged us to in-
vestigate partial T cell-depleted allogeneic SCT in
the RIC setting, combined with preemptive immuno-
therapy with DLI. The major advantage of T cell-de-
pleted grafts is reduction of severe and prolonged
GVHD, but effective posttransplantation immuno-
therapy is essential to overcome the higher rate of
relapse. As a novel approach we incorporated recipi-
ent-derived dendritic cell (DC) vaccination in the
posttransplantation strategy for patients with residual
disease after two preemptive DLI dosages.
DC are the professional antigen-presenting cells
(APCs) of the immune system, and are essential for
the induction of antigen-specific T cell immunity. In
the setting of allogeneic SCT and DLI, alloreactive
T cell responses targeting minor histocompatibility
antigens (MiHA) on malignant cells of the recipient
can be induced directly by recipient-derived DC and
indirectly by donor-derived DC because of crosspre-
sentation [6]. Boosting GVM immunity by vaccination
with donor-derived DC loaded with hematopoiesis-
restricted MiHA seems most ideal, but this approach
is hampered by the limited number of known MM-
expressed MiHA. Studies in mouse models demon-
strated that recipient DC play a pivotal role in the
initiation of alloreactive CD81 T cell-mediated
immunity against leukemia [7,8]. Moreover, the pres-
ence of recipient DC in the setting of mixed chimerism
has a positive impact on the effectiveness of DLI [9].
Because recipient DC and myeloma tumor cells are
both derived from the hematopoietic system, immune
responses induced by recipient-derived DC may
enhance GVM with limited GVHD in other tissues,
like mucosa, liver, and skin.
Here, we show the results of partial T cell-depleted
RIC-SCT after autologous transplant for MM, with
limited GVHD and a low 1-year TRM of 10%.
Furthermore, we investigated the feasibility of gener-
ating mature recipient-derived DC from cryopre-
served apheresis products, the immunogenicity of the
vaccine, and the toxicity of recipient-derived DC vac-
cination. Our study indicates that partial T cell-
depleted RIC-SCT is feasible, results in excellent
engraftment, and offers opportunities for posttrans-
plantation cellular immunotherapy with DLI in some
patients combined with DC vaccination. Importantly,our approach keeps open the treatment with novel
agents (bortezomib and lenalidomide) in case of
progressive or relapsed disease even in combination
with DLI.MATERIALS AND METHODS
Transplantation Procedure
From January 2006 to May 2008, 20 patients have
been included in a pilot study of partial T cell-depleted,
allogeneic RIC-SCT for MM. All patients were pre-
treated for symptomatic MM with induction chemo-
therapy and high-dose melphalan (HDM), followed by
autologous SCT (conform HOVON-50 or HOVON-
65 studies or standard induction scheme at that time)
[10]. Patients\65 years with an HLA-identical sibling
donor were offered upfront allogeneic RIC-SCT within
6 months after autologous transplant, regardless of risk
factors or disease status. Before RIC-SCT, autologous
PBMC were collected by apheresis, washed to deplete
platelets, and cryopreserved for posttransplant DC vac-
cination (Figure 1). The conditioning regimen consisted
of cyclophosphamide (Cy) 1200 mg/m2 .v. in combina-
tion with fludarabine (Flu) 30 mg/m2 on each of 4 con-
secutive days (days 25, 24, 23, and 22 before SCT).
Donor stem cell grafts were depleted from T and B cells
by anti-CD3 and anti-CD19 immunomagnetic beads
(Miltenyi Biotec, Bergisch Gladbach, Germany). Fol-
lowing depletion, CD31 T cells were added back to
generate a stem cell graft containing a fixed number of
0.5 106 T cells/kg body weight of recipient. GVHD
prophylaxis consisted of Cyclosporine A (CsA) 3 mg/
kg/day .v. starting on day 21 until CsA could be taken
orally. CsA was administered orally at a dose of 6 mg/
kg/day until 8-10 weeks after SCT followed by a gradu-
ally tapering off in 4 weeks. Acute and chronic graft-ver-
sus-host disease (aGVHD, cGVHD) were classified
grade I-IV and limited or extensive, respectively, accord-
ing to the criteria described by Glucksberg [11] and
Shulman [12].
Evaluation of Response and chimerism Analysis
Responses were evaluated according to the
response criteria for MM described by Durie et al. in
2006 [13]. Bone marrow (BM) aspirates during post-
transplantation immunotherapy were performed in
patients receiving DC vaccination. Lambda free light
chains were measured using the serum free light chain
(FLC) assay (Freelite, Birmingham, UK). For measur-
ing kappa free light chains, we used the ELISA assay, as
described by Lamers et al. [14]. This ELISA was
shown to parallel FLC kappa assay, with lower abso-
lute values. To define CR, the FLC ratio was measured
with the Freelite assay for both lambda and kappa free
light chains. The data were analyzed in December
2008.
Figure 1. Flow chart of the tandem autologous SCT followed by
RIC-SCTand posttransplantation cellular immunotherapy.
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tient-specific IgH-polymerase chain reaction (PCR)
[15]. The sensitivity of the PCR is 1 1025. The
patient-specific IgH-PCR did not play a role in the
decision on the treatment schedule, because molecular
analysis of disease load in BM was performed retro-
spectively.
Real-time quantitative PCR of single nucleotide
polymorphisms (SNP) and/or the SMCY gene was
used for chimerism analysis as described previously
[16-18]. Briefly, recipient/donor pairs were screened
for discriminating SNPs. Quantification was based
on real-time PCR with allele-specific primers for
DNA-sequences containing the discriminating SNP
and target DNA-specific probes.
Posttransplantation Immunotherapy:
Treatment Schedule
Patients without aGVHD grade .II and without
cGVHD after RIC-SCT, were candidates for preemp-
tive DLI 4 weeks after discontinuation of immunosup-
pression. The first DLI dose consisted of 1.0 106 T
cells/kg body weight and the second dose 2 months later
of 5.0 106 T cells/kg body weight (Figure 1). Patients
with residual disease after 2 DLIs were eligible for
recipient-derived DC vaccination. Exclusion criteria
for vaccination were progressive disease (PD), extensive
or uncontrolled GVHD, recent use of immunosuppres-
sive drugs, and active infections. Vaccinations were ad-
ministered 3 times at 2-week intervals. The DC dosewas maximal at 30 106 cells i.v. as a bolus injection
and 15 106 DCs intradermally (i.d.) in the upper leg
near the inguinal lymph node region. If the yield of ma-
ture DC was too low, then only i.v. vaccination was
given. Blood samples were taken from these patients be-
fore vaccination, on day 14 (after first vaccination), on
day 28 (after second vaccination), on day 42 (after third
vaccination), and on day 56 (28 days after the third vac-
cination). If no GVHD was induced, residual disease
persisted and sufficient DC were cryopreserved, a sec-
ond series of vaccinations was started using the combi-
nation of DC vaccination with DLI 5.0 106 T cells/
kg body weight.
The study was approved by the Local Ethics
Committee of Radboud University Nijmegen Medical
Centre.
Posttransplantation Immunotherapy:
Generation of DC Vaccine
DC vaccines were generated under good manu-
facturing practice conditions in a clean room facility.
Before the conditioning for RIC-SCT, patient periph-
eral blood mononuclear cells (PBMCs) were collected
by leukapheresis of 9 liters of blood using the Cobe
Spectra aphaeresis system (Gambro BCT, Breda,
The Netherlands). PBMC were washed with Clini-
MACS buffer containing 5% human serum albumin
(HSA) to deplete from platelets, cryopreserved in
HSA plus 10% DMSO and stored in liquid nitrogen
until use. For culturing DC, PBMC were rapidly
thawed at 37C and resuspended in CliniMACS buffer
containing 100 U/mL Pulmozyme (Roche, Woerden,
The Netherlands), 3 mM MgCl2, and 5% HSA. After
a 30-minute incubation, PBMC were centrifugated,
washed, and resuspended in XVIVO-15 medium
(Cambrex Bio Sciences, Verviers, Belgium) plus 2%
heat-inactivated virus-free human serum (HS). Mono-
cytes were isolated by plastic adherence and cultured in
XVIVO-15/2% HS supplemented with 800 U/mL
GM-CSF and 500 U/mL IL-4 (CellGenix, Freiburg,
Germany). Cells were harvested at day 3, counted
and cultured at 0.5  106 cells/mL in 6-well plates in
XVIVO-15/2% HS containing granulocyte macro-
phage-colony stimulating factor (GM-CSF) (800 U/
mL), IL-4 (500 U/mL), and 50 mg/mL keyhole limpet
hemocyanin (KLH) subunits (Biosyn Arzneimittel
GmbH, Fellbach, Germany). Two days before harvest-
ing, KLH-loaded DC were maturated in XVIVO-
15/2% HS containing GM-CSF (800 U/mL), IL-4
(500 U/mL), IL-1b (5 ng/mL), IL-6 (15 ng/mL),
TNF-a (20 ng/mL) (all CellGenix Freiburg,
Germany), and prostaglandin E2 (PGE2; Pharmacia
& Upjohn, Puurs, Belgium, 1 mg/mL). Mature DC
were harvested at day 9 and tested for microbial and
phenotypic analysis. One-third of the cells were used
for immediate injection and remaining cells were cryo-
preserved for subsequent vaccinations.
Table 1. Characteristics of MM Patients
Characteristic Number
Number of patients 20
Median age at transplantation, years (range) 57 (39-64)
Sex, no (%)
Male 11 (55%)
Female 9 (45%)
Immunoglobulin class (%)
IgG 11 (55%)
IgA 3 (15%)
Light chain 6 (30%)
Cytogenetics 17
Karyotypic analysis
Normal 11
Deletion of chromosome 13* 1
Hyperdiploid/complex 5
Interphase FISH
Deletion of chromosome 13 7
Beta2-microglobulin
<3.5 mg/L 5
>3.5 mg/L and <5.5 mg/L 3
$5.5 mg/L 1
Not done 11
Induction chemotherapy
VAD 16
TAD 2
PAD 2
VAD indicates vincristine, doxorubicin, dexamethasone; TAD, thalido-
mide, doxorubicin, dexamethasone; PAD, Bortezomib, doxorubicin,
dexamethasone; FISH, fluorescein in situ hybridization; MM, multiple
myeloma.
*Deletion of chromosome 13 by metaphase cytogenetics.
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T cell responses against KLH were measured using
the 3H-thymidine incorporation assay with PBMC of
the patient before and after vaccination. Briefly,
PBMC were restimulated in vitro with 50 mg/mL
KLH subunits or 1 mg/mL PHA plus 100 U/mL IL-2
(ie, positive control). At day 7 of incubation, T cell
proliferation was determined by 3H-thymidine incor-
poration. The stimulation index was calculated as the
counts ratio between stimulated and nonstimulated
PBMC. Antibodies against KLH were measured in
the serum of vaccinated patients by ELISA as described
by De Vries et al. [19] A positive signal at a 400 dilu-
tion of the patient’s serum was considered positive.
Alloreactive CD81 T cell responses against recipi-
ent MiHA were determined by major histocompatibil-
ity complex (MHC) tetramer staining. Therefore,
patients and donors were first genotyped for known
MiHA-mismatches using allele-specific PCR assays as
described previously [20,21]. In case of MiHA mis-
matches, PBMCs were incubated with the appropriate
phycoerythrin (PE)-labeled MHC tetramer complex
for 20 minutes at room temperature. After washing
with PBS/0.5% BSA, cells were labeled with the appro-
priate concentration anti-CD8-FITC (ProImmune,
Oxford, UK), anti-CD3-PECy7, and anti-CD45-
ECD (Beckman Coulter, Fullerton, CA) for 15 minutes
at 4C. After washing, cells were resuspended in PBS/
0.5%BSA and 7-amino-actinomycin D (7AAD; Sigma,
St. Louis, MO, USA) was added. Cells were analyzed
using the Coulter FC500 flow cytometer (Beckman
Coulter).RESULTS
Patient Characteristics
Twenty MM patients received upfront allogeneic
RIC-SCT after autologous SCT between January
2006 and May 2008 (Table 1). Median age of these
patients was 57 years (range: 39-64 years) at the time
of RIC-SCT and of these 20 patients 11 were male
and 9 were female. Disease status following autologous
SCT was complete response (CR) in 7 patients (35%),
very good partial response (VGPR) in 2 (10%), partial
response (PR) in 8 (40%), stable disease (SD) in 2
(10%), and PD in 1 patient (5%). These results are
comparable to the outcome after autologous SCT in
other studies [4].RIC-SCTwith Partial T Cell-Depleted Grafts
Resulted in successful Engraftment with Limited
GVHD
All 20 patients received PB stem cell (PBSC) grafts
from HLA-identical sibling donors. Median number
of infused CD341 cells was 8.3 106 per kg bodyweight of the recipient (range: 4.3-12.8 106). Median
number of infused CD31 T cells was 0.50 106 per kg
(range: 0.31-0.77 106). Furthermore, median num-
ber of infused B cells was 0.22 106 per kg (range
0.05-0.75 106) and median number of infused NK-
cells was 34.5 106 per kg (range: 7.9-97.1 106).
After RIC-SCT, median time to reach leukocyte
counts .1.0 109/l and platelet counts .20 109/l
was 13 days (range: 10-20 days) and 9 days (range:
0-11 days), respectively. In 3 patients platelet counts
did not decline to below 20 109/l.
Nineteen patients could be evaluated for PB cell
chimerism at 3 months after RIC-SCT, and 1 patient
died 2.2 months after RIC-SCT. All 19 patients
showed successful donor engraftment and there was
no secondary graft failure. At 3 months, 7 patients
were complete donor chimeric and 12 patients were
mixed chimeric. In these 12 mixed chimeric patients,
the median value of autologous PBSCs was 7% (range:
2%-27%). Two patients converted to complete donor
chimerism after discontinuation of CsA at 5 and 6
months after RIC-SCT, respectively. At the last
follow-up, 16 of the 19 patients were complete donor
chimeric, and 3 patients were still mixed chimeric.
These 3 patients included 1 patient in which the
donor was unavailable for donating lymphocytes and
2 patients treated with pre-emptive DLI shortly before
or after the last follow-up.
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III or IV aGVHD. Grade II aGVHD occurred in 7 of
20 (35%) patients. Nineteen patients were evaluable
for cGVHD, of whom only 4 (21%) developed
cGVHD. The median duration of CsA treatment
was 99 days (range: 58-230 days). In 9 patients, CsA
could be discontinued within 100 days. Three patients
with cGVHD received CsA for more than 5 months.Clinical Response after Partial T Cell-Depleted
RIC-SCTand Preemptive DLI
Nineteen patients could be evaluated for clinical
response at 3 months after RIC-SCT. Eight patients
(42%) were in CR, 1 (5%) patient in VGPR, 7 (37%)
patients in PR, and 3 patients had SD after the auto/
RIC-SCT tandem-procedure.
Twelve of the 19 patients (63%) received preemp-
tive DLI of 1.0 106 T cells/kg after RIC-SCT, and 7
of these patients also received a second dose-escalated
preemptive DLI of 5.0 106 T cells/kg. Details of
these twelve patients are shown in Table 2. Only 1 of
the 12 patients developed GVHD grade I after
preemptive DLI.
Two patients (UPN2 and UPN17) reached CR af-
ter preemptive DLI in a dose of 5.0 106 T cells/kg
(Figure 2A and B). For patient UPN2, a patient-
specific IgH-PCR was developed and this PCR became
negative after preemptive DLI indicating molecular
remission. Furthermore, 3 patients (UPN1, UPN3,
and UPN7) converted to complete donor chimerismTable 2. Disease Status and Chimerism in Patients Receiving Pree
UPN M-protein
Disease Status 3 Months
after RIC-SCT*
Chimerism 3 Months
after RIC-SCT
1. IgG-kappa CR 2.1% recipient cells
2. IgG-kappa PR 5.2% recipient cells
3. Light chain l PR 26.7% recipient cells
4. IgG-kappa PR Complete donor
5. IgG-k SD Complete donor
7. Light chain l CR 14.0% recipient cells
8. IgG-kappa CR Complete donor
10. IgA-k PR 8.6% recipient cells N
12. IgA-k PR Complete donor
13. IgG- l PR Complete donor
14. IgG- k SD 9.5% recipient cells
15. Light chain l CR 2.2% recipient cells
17. IgG-lambda PR 6.9% recipient cells
19. Light chain k CR 5.5% recipient cells
CR indicates complete remission; VGPR, very good partial response; PR, part
conditioning-stem cell transplantation; DLI, donor lymphocyte infusion; DC, d
*Response 3 months after RIC-SCT.after posttransplantation immunotherapy with DLI,
6, 22, and 25 months after SCT, respectively.
Seven of the 19 patients did not receive preemptive
DLI, because of GVHD (n5 4), infections (n5 2),
and donor unavailability in 1 patient.Generation of Recipient-Derived DC Vaccines
Following preemptive DLI, DC vaccines were gen-
erated for 6 patients as part of posttransplantation
immunotherapy. Therefore, the cryopreserved aphere-
sis product collected just prior RIC-SCT was thawed
and used to generate mature monocyte-derived DC
of recipient origin. Preclinical investigations showed
that mature DC could be generated from cryopre-
served apheresis products of MM patients that effi-
ciently stimulated allogeneic T cell proliferation in
vitro (Figure 3). The yield of PBMC and CD141
monocytes postcryopreservation for the 6 patients
was 45% to 90% and 25% to 57%, respectively
(Figure 4A). DC culture from cryopreserved PBMC re-
sulted in sufficient DC yield in 4 patients (ie, 9%-16%
from CD141monocytes), but for 2 patients only a lim-
ited number of DC could be obtained (yield\5% from
CD141 monocytes). The final vaccine contained
.95% viable DCs (Figure 4A). Furthermore, DC
vaccines had a very mature phenotype with .85%
expression of CD83 and the costimulatory molecules
CD80, CD86, and CD40 (Figure 4B). Moreover,
58% to 95% of the DC in the vaccines expressed the
lymph-node migration receptor CCR7. For 1 patient,
we did not obtain good quality mature DC, and thismptive DLI after RIC-SCT
Preemptive DLI: T
Cells/kg Body Weight
Outcome after Preemptive
DLI (after Second DLI)
1.0 106 CR, complete donor chimerism,
Guillain-Barre syndrome, died
13 months after SCT from pneumonia
1.0 106 and 5.0 106 CR, complete donor chimerism,
DC vaccination
1.0 106 and 5.0 106 VGPR, 6.7% recipient cells,
DC vaccination
1.0 106 and 5.0 106 PR, ongoing decline of M-protein
1.0 106 and 5.0 106 SD, DC vaccination
1.0 106 and 5.0 106 CR, 12.8% recipient cells,
DC vaccination
No preemptive, but
therapeutic DLI
VGPR after therapeutic DLI for
relapse, DC-vaccination
o DLI, donor not available Not applicable, DC vaccination
1.0 106 and 5.0 106 Relapse
1.0 106 and 5.0 106 PR, DC vaccine did not
fulfill quality criteria
1.0 106 Relapse, 1.8% recipient cells
1.0 106 Relapse, 1.1% recipient cells
5.0 106 CR, 1.0% recipient cells
1.0 106 CR, second preemptive
DLI is planned
ial response; SD, stable disease; RIC-SCT, reduced-intensity
endritic cell.
Figure 2. Clinical course of patient UPN2 (A) and patient UPN17 (B). The Y-axis on the left shows disease load as measured by serum FLCs or
M-protein, and is shown with the green line. The Y-axis on the right shows the percentage recipient cells in peripheral blood and is shown with a purple
line. Triangle in blue indicates autologous SCT, triangle in red indicates RIC-SCT, triangle in orange indicates DLI, and triple-triangle in blue indicates 1
cycle of DC-vaccinations.
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cause of the variability in the yield of DC from thawed
PBMC, the number of administered DC varied. Four
patients received at least 1 maximum dose, 1 patient
received 3 vaccinations each with total 10  106 cells
(i.v. and i.d.) and 1 patient received 3 i.v. vaccinations
each with 4  106 cells (Table 3).Vaccination with Recipient-Derived DC
Vaccines after RIC-SCT
Six MM patients were vaccinated with recipient-
derived DC (Tables 2 and 3). The median time
from RIC-SCT to DC vaccination was 11.6 (range:8.1-24.4) months. Median interval from last DLI to
DC vaccination was 4.2 (range: 3.5-4.9) months.
Four patients were vaccinated after 2 preemptive
DLIs. In 1 patient, the donor was no longer available
for donating lymphocytes, and she was treated with
DC vaccination only as posttransplantation immuno-
therapy. The sixth patient was treated with DC vacci-
nation following 2 therapeutic DLIs. None of these
patients showed clinically active disease at the time
of vaccination.
DC were loaded with the antigenic protein KLH
as an adjuvant to provide CD41 T cell help and for
boosting of alloreactive CD81 T cell responses as
well as to analyze the induction of a primary immune
response posttransplantation. All patients showed
Figure 3. (A) Preclinical study of characteristics of mature DC generated from cryopreserved apheresis products from 4 MM patients. Apheresis was
performed after autologous SCT. Cultured DC had a mature phenotype with high expression of CD83, CD80, and CD86. (B) In vitro stimulation
capacity of mature DC generated from cryopreserved apheresis products. DC from patients 1 and 2 and patients 3 and 4 were tested with responder
cells from different healthy donors.
326 Biol Blood Marrow Transplant 16:320-332, 2010H. Levenga et al.a PB T cell proliferative response against KLH that
could already be detected after 1 single DC vaccination
(Table 3 and Figure 5A). However, the anti-KLH T
cell proliferative response in some patients decreased
following subsequent DC vaccinations (Figure 5A).
Furthermore, antibody responses against KLH could
not be detected (Table 3).
Five patients were evaluated for T cell recovery at
the time of DC administration (Table 4). Median
CD31 T cell count was 0.7 109/L, median CD41 T
cell count 0.3 109/L, and median CD81 T cell count
was 0.4 109/L, indicating a not completely recovered
immune system, especially from the CD41 T cells at
the time of vaccination. Natural killer (NK) cells
were recovered to normal in 4 of the 5 patients with
a median of 0.2 109/L CD32CD16/561 NK cells.
CD4/CD8 ratios were still inversed in 3 of the 5
patients. Although CD41 and CD81 T cell counts
were not completely recovered to normal levels, all 5
patients showed a strong in vitro polyclonal T cell
proliferative response upon stimulation with PHA
and IL-2 (Table 4).
Impact of DC-vaccination on regulatory T cells
has been studied before and after each DC vaccination.
Regulatory T cells were studied as the percentage of
CD25 bright1 cells within the CD31CD41 popula-
tion and are shown in Figure 5B. There is no trend
in increasing percentages of CD41CD25 bright1 cells
in DC vaccinated patients.Characterization of T Cell Responses
For all 6 patients who received DC vaccination, we
performed genomic typing of 12 previously described
MiHA. In 2 patients, a mismatch against a knownMiHA was found with the immunogenic allele in the
recipient. Patient UPN2 was mismatched for MiHA
HY and patient UPN5 for HA-8. PB samples (before
and after DLI as well as before and after DC vaccina-
tion) of patient UPN2 were analyzed with tetramers
against HLA-A2 and HLA-B7 restricted epitopes in
the male-specific SMCY protein. However, in these
samples no SMCY-tetramer-positive cells could be de-
tected (data not shown). Samples of patient UPN5 (be-
fore DC vaccination and after each DC vaccination)
were analyzed with tetramers against the HLA-A2 re-
stricted HA-8 antigen. Also in this patient we found no
HA-8 tetramer positive cells in PB samples (data not
shown). Although we could not detect tetramer-posi-
tive T cells against known MiHA in DLI and DC-
treated patients, this does not exclude the presence of
MiHA-specific or tumor antigen-specific T cell re-
sponses in these patients.Recipient DC Vaccination Did Not Induce
Severe Toxicity and GVHD
Toxicity of recipient DC vaccination was limited to
flu-like symptoms with mild fever and local induration
at the injection site (Table 3). Importantly, none of
the 6 patients developed clinical signs of GVHD, but
2 patients developed discrete dermal changes with fol-
liculitis and eosinophilia in peripheral blood (PB).
At the time of the first DC vaccination, 3 patients
were complete donor chimeric and 3 patients had still
mixed chimerism with 6.7%, 12.8%, and 8.6% recipi-
ent cells, respectively (Table 2). DC vaccination alone
did not induce conversion to complete donor chime-
rism. Patient UPN3 converted to complete donor
chimerism after a second cycle of vaccinations in
Figure 4. (A) Characteristics of DC vaccine from thawed apheresis
products. Postcryopreservation, the yield of PBMC varied from 45%
to 90% and yield of CD141 monocytes varied from 25% to 57%. Yield
of mature DC from CD141 cells was sufficient in 4 patients (9%-
16%); however,\5% in 2 patients. Viability of the vaccination product
was .90% for all administered vaccines. (B) DC vaccine phenotype.
All administered DC vaccines had a mature phenotype with high expres-
sion of the cell surface antigens CD83, CD80, CD86, and CCR7.
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received a therapeutic DLI of 0.5  108 T cells/kg for
increase of free light lambda chains, resulting in com-
plete donor chimerism and GVHD grade II (Figure 6B).Table 3. Immune Responses and Toxicity after recipient DC Vaccin
Number of Vaccinated DC*
UPN Vac I Vac II Vac III DLI†
3. 30/15 30/15 29/13 no
6.5/3.5 6.5/3.5 5/2.5 DLI (5.0 106 /kg)
5. 4/0 4/0 3/0 No
7. 30/15 33/15 34/17 No
10. 28/14 27/13 27/13 No
2. 7/3 7/3 6.5/3.5 No
8. 30/15 18/9 18/9 DLI (10.0 106 /kg)
DLI inidcates donor lymphocyte infusion; MM, multiple myeloma; GVHD, graf
*Cell numbers are given in 106, intravenously/intradermally.
†Two patients received the combination of DLI and DC vaccination. UPN3 rece
vaccination I. UPN 8 relapsed after RIC-SCT, and responded to therapeutic
combination with DLI. DLI was coinfused with DC-vaccination II.
‡Local induration was not applicable to this patient.
§KLH-specific proliferation of PBMC after vaccination is depicted as stimulatio
¶KLH-specific antibody titers in serum after vaccination: – no Ab or <1:400; +Clinical Outcome of DC Vaccination
after RIC-SCT
Fourteen of 20 patients were treated with post-
transplantation immunotherapy (13 preemptive and
1 for relapse), including 8 patients with preemptive
DLI alone, 5 patients received both DLI and DC vac-
cination and 1 patient DC vaccination only (Table 2).
DC vaccination in 6 patients did not result in in-
duction of responses by itself. However, patient
UPN3 showed a gradual decline of light chains after
RIC-SCT during posttransplantation immunotherapy
with DLI and DC vaccinations (Figure 6A). Two years
after RIC-SCT, light chains started rising again with-
out clinical symptoms. An escalating dose of DLI was
administered, but the serum free light chains contin-
ued to rise. Presently, this patient is treated with the
combination of lenalidomide and DLI.
Patient UPN7 showed a rise in FLC lambda
8 months after completion of DC vaccination
(Figure 6B). Although this rise did not fulfill the crite-
ria for PD, immunotherapy was continued because in
our experience rise of FLCs predicts clinical relapse.
He was treated with therapeutic DLI (0.5  108 T
cells/kg) and developed GVHD grade II in combina-
tion with stabilization of free light lambda chains. Pa-
tient UPN5 and UPN10 did not respond to DC
vaccination.
Patient UPN8 reached a VGPR after 2 therapeutic
DLIs of 5.0 and 10.0 106 T cells/kg for relapsed MM
(Figure 7). Because of the relapse, DC vaccination was
combined with DLI in a dose of 10.0 106 T cells/kg.
At the last follow-up, immunofixation remains positive
but the M-protein cannot be quantified.
OS and PFS after RIC-SCT
With a median follow-up for surviving patients of
27 months (range: 8.9-34.9 months) the OS is 84%
(Figure 8A). TRM was 5% at 100 days, and 10% at
1 year. One patient died from sepsis and cardiac failureation
Anti-KLH response
Induration Fever GVHD T cell§ Ab¶
yes yes no +++ –
no no no
na‡ no no +++ –
Yes yes no +++ –
Yes yes no +++ –
Yes yes no ++ –
No no no + –
t-versus-host disease; DC, dendritic cell.
ived a second cycle of vaccinations in combination with DLI on the day of
DLI. Because of relapsed MM, this patient received DC-vaccination in
n index (SI): + SI > 2 < 10; ++ SI$ 10 < 100; +++ SI$ 100.
Ab titer $1:400.
Figure 5. (A) KLH specific T cell proliferation indicated as stimulation
index. (B) Regulatory T cells (CD25 bright1 cells within the
CD31CD41 population) before and after each DC vaccination in 5 pa-
tients treated with DC vaccination.
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nary cGVHD 9 months after RIC-SCT. One addi-
tional patient died in CR 13 months after RIC-SCT
from the complications of pneumonia during recovery
from a Guillain-Barre syndrome. None of the patients
died from relapsed or progressive multiple myeloma.
At the last follow-up in December 2008, 6 patients
were in CR, 1 patient reached a VGPR, and 2 patients
with PR were still receiving immunotherapy. Eight
patients had started with systemic therapy (bortezo-
mib, thalidomide, or lenalidomide) for PD afterTable 4. T cell Recovery at Time of DC Vaccination
UPN
Interval SCT-DC
Vaccination (Months) CD3+ 109/L
CD3
CD16/56+
Normal (5-95 percentile) 1.2 (0.7-2.1) 0.3 (0.09
3. 11.8 0.7 0.23
1.5 0.64
5. 11.3 0.8 0.2
7. 11.3 0.8 0.2
10. 8.1 0.3 0.12
2. 14.4 0.7 0.06
DC indicates dendritic cell; SCT, stem cell transplantation.
*PHA/IL2 induced proliferation of PBMC before vaccination is depicted as stim
++++ SI$ 500.RIC-SCT (3 from SD, 2 with PR, and 1 with
VGPR) or relapse from CR (2 patients). The current
PFS is shown in Figure 8B.DISCUSSION
Here, we report on the feasibility of Flu-Cy RIC-
SCT in combination with a partial T cell-depleted
graft for MM patients following induction chemother-
apy and autologous transplant with HDM. One-year
TRM was reduced to 10% in a cohort of 20 patients
with a median follow-up of surviving patients of 27
months. This TRM is in line with other studies using
RIC-SCT for MM [1,4]. OS rate is comparable with
other studies in patients undergoing autologous SCT
followed by RIC-SCT. In our study, OS was 84% at
2 years. In the ECOG-study the actuarial survival
rate at 2 years was 78% and OS was 78% at 20 months
in the study from Maloney et al. [1,22]. All patients
showed donor engraftment and no late graft failures
occurred. Importantly, aGVHD was limited to grade
I and II, and could be managed with CsA and cortico-
steroids. The prevalence of cGVHD was 21%, includ-
ing 1 patient suffering from pulmonary disease,
probably related to GVHD. The duration of immuno-
suppressive therapy with CsA was relatively short for
a RIC regimen with a median of 99 days, 3 patients
were treated with CsA for more than 5 months because
of cGVHD.
Preemptive DLI resulted in conversion from PR to
CR in 2 patients. At the last follow-up, 6 of the
17 evaluable patients were in CR and 3 of them have
received preemptive DLI. However, durability of
these responses with a median follow-up of 27 months
has to be shown by a longer follow-up. DC-vaccina-
tion alone did not induce GVM responses after RIC-
SCT. However, this study was designed to analyze
the feasibility, immunogenicity, and toxicity of recipi-
ent-derived DC vaccination. Important questions con-
cerning the optimal dose of DC, route of
administration, and combination with DLI have not
been studied yet in the setting of allogeneic SCT.2
 109/L CD19+ 109/L CD4+ 109/L CD8+ 109/L
PHA/IL2
Response*
-0.6) 0.2 (0.1-0.5) 0.7 (0.3-1.4) 0.4 (0.3-1.4)
0.2 0.4 0.3 +++
0.07 1.6 0.7
0.0 0.2 0.5 ++++
0.05 0.4 0.4 ++++
0.08 0.2 0.1 ++++
0.22 0.2 0.6 ++++
ulation index (SI): + SI > 2 < 10; ++ SI$ 10 < 100; +++ SI$ 100 < 500;
Figure 6. Clinical course of patient UPN3 (A) and patient UPN7 (B). The Y-axis on the left shows disease load as measured by serum FLCs or
M-protein, and is shown with the green line. The Y-axis on the right shows the percentage recipient cells in peripheral blood and is shown with a purple
line. Triangle in blue indicates autologous SCT, triangle in red indicates RIC-SCT, triangle in orange indicates DLI, and triple-triangle in blue indicates 1
cycle of DC vaccinations.
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SCT creates a platform for posttransplantation cellu-
lar immunotherapy with preemptive DLI and DC
vaccination, given the low incidence and severity of
GVHD and the short duration of immunosuppressive
therapy. DLI has proved to be effective in MM as pre-
emptive immunotherapy; however, the optimal dose
and timing is not known [23]. In this study, preemptive
DLI started with a low dose of 1.0 106 T cell/kg
4 weeks after discontinuation of CsA followed by a sec-
ond dose of 5.0 106 T cells/kg 2 months later. The
lowest dose of 1.0 106 T cell/kg did not result in
GVM reactivity, or in GVHD. Conversion of chime-
rism was observed in only 1 patient after this low-dose DLI. The dose of 5.0 106 T cells/kg resulted
in CR in 2 patients without GVHD. Therefore, we ap-
ply a starting DLI dose of 5.0 106 T cells/kg in the
current protocols.
Repeated DLIs were only given if a patient did not
reach CR. Importantly, most responses to DLI were
seen after the first or second DLI. Only 1 patient
developed GVHD and decreasing FLCs after the third
DLI. Repeated DLIs were given to patients with
relapsed MM after RIC-SCT who responded to sys-
temic therapy with Bortezomib or Lenalidomide
(data not shown). These repeated DLIs did not result
in long-term remissions. We consider most patients
not responding to the first or second DLI resistant to
Figure 7. Clinical course of patient UPN8. The Y-axis on the left shows disease load as measured by serum FLCs or M-protein, and is shown with the
green line. The Y-axis on the right shows the percentage recipient cells in PB and is shown with a purple line. Triangle in blue indicates autologous SCT,
triangle in red indicates RIC-SCT, triangle in orange indicate DLI and triple-triangle in blue indicate 1 cycle of DC vaccinations.
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by DLI are effective antigen presentation and costimu-
lation in conjunction with sufficient inflammation. In
this study, we have been focusing on the antigen pre-
sentation, and introduced DC-vaccination as post-
transplantation immunotherapy. Another strategy to
further boost GVM immunity after DLI could be
blockade of negative regulatory mechanisms. For
example, strategies aimed at reducing regulatory
T cells or blocking of the T cell inhibitory PD-1/
PD-L1 pathway.
Although preemptive DLI is effective, other
therapies are needed to further improve the GVM
effect of RIC-SCT. Both regulatory T cells and
host APCs have been implicated in GVHD and
graft-versus-leukemia (GVL) reactivity after DLI.
The requirement of recipient APC for the induction
of GVL has been clearly demonstrated by Mapara
et al. [9]. Moreover, Xia et al. [24] have shown that
in the long-term, complete chimeras loss of DLI-in-
duced GVL can be restored by infusion of host DC.
In this study, we analyzed the feasibility of generat-
ing recipient-derived mature DC and the toxicity of
vaccination with these DC.
To generate recipient-derived mature DC several
months after allogeneic SCT, we used cryopreserved
patient apheresis products obtained after autologous
SCT and shortly before RIC-SCT. DC with a mature
phenotype and sufficient CD80, CD83, CD86,
and CCR7 expression could be generated from the
cryopreserved PBMC from 6 of 7 patients. The
administered vaccine products all fulfilled the quality-
criteria as described by Figdor et al. [25]. The generated
DC of 1 patient did not have a mature phenotype.Comparative studies with immature and mature DC
have demonstrated that only mature DC stimulate T
cell in vivo and it has been shown that immature DC
can silence immune responses [19]. Therefore, this
not fully mature DC vaccine was not administered.
Induction of a primary immune response was mea-
sured by T cell responses against KLH. We showed
that recipient-derived mature DCs loaded with KLH
induce a potent primary T cell response after the first
vaccination. However, the PB T cell proliferative re-
sponse against KLH after the second and third DC in-
jection decreased in most patients. DCs were not extra
loaded with antigens because recipient-derived DCs
are able to directly present recipient-specific MiHA
to donor T cells. In this setting of using unloaded
recipient-derived DC, we aimed at the induction of
MiHA-specific donor T cell responses against known
and unknown MiHA. Genotyping for known MiHA
in the vaccinated recipients and their donors did
identify MiHA-mismatches in some patients that
could be involved in GVM and GVHD (data not
shown). However, we were unable to detect antigen-
specific T cells against known MiHA using tetramer
staining. Currently, we are analyzing whether recipi-
ent-derived DC did boost or induce T cell responses
against unknown MiHA by functional characterization
of alloreactive T cell lines generated from vaccinated
patients.
Toxicity of recipient-derived DC was limited to
fever the evening after the second and third vaccina-
tion and local induration at the injection site. Such tox-
icity is known from other vaccination studies, and
probably results from immune responses against
KLH [26]. None of the 6 patients developed GVHD
Figure 8. OS of 20 patients after RIC-SCTwith a median follow-up of
27 months. (A) Current PFS of 20 patients after RIC-SCT. Progression
was noted when systemic therapy was started.
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patients reported discrete skin changes.
This is the first study that applied recipient-derived
DC vaccines after allogeneic SCT. One major limita-
tion of recipient-derived DC vaccines after allogeneic
SCT is the requisite to collect and to cryopreserve
PBMC before SCT for generation of mature mono-
cyte-derived DC several months later. Alternatively,
donor DC loaded with recipient-specific MiHA may
also induce alloreactive T cell responses after alloge-
neic SCT and the use of donor-derived DC for vaccina-
tion circumvents the obstacle of cryopreservation. To
explore donor-derived DC vaccines for the induction
of MiHA-specific immune responses after SCT, a set
of hematopoietic-restricted MiHA with expression on
tumor cells must be available for loading of donor-
derived DC. Until now, the number of identified hema-
topoietic-restricted MiHA with expression on MM
tumor cells was limited, and therefore hampered the
application of this strategy. However, the proof of prin-
ciple may be explored clinically by using MiHA HA-1
and LRH-1, which have been shown to be functionally
expressed by MM tumor cells [27,28].Vaccination with donor-derived DC, loaded with
tumor lysate or tumor-associated antigens, after SCT
has been published before in 3 reports. In the first
report, DC were cultured from granulocyte colony-
stimulating factor (G-CSF) mobilized PB stem cells
from the donor [29]. Donor-derived DC pulsed with
irradiated tumor cells and primed T cells were injected
in 4 patients with relapse after SCT. In the second re-
port, DC cultured from PB cells from the donor and
pulsed with tumor lysate were given to a patient trans-
planted for metastatic renal cell carcinoma [30].
Vaccination with donor-derived DC appeared to be
safe in this single patient, but did not induce graft-
versus-tumor reactivity. In the third report, a patient
with relapsed acute myelogenous leukemia (AML) af-
ter SCT was vaccinated with WT1 peptide and
KLH-pulsed donor-derived DC [31]. Immune re-
sponses were induced to the immunogenic antigen
KLH, however T cell responses against WT1 were
not detected and the relapsed leukemia did not re-
spond.
New options to salvage patients with relapsed or
PD after allogeneic SCT are thalidomide, bortezomib,
and lenalidomide. El-Cheikh et al. [32] reported 37 pa-
tients treated with bortezomib as salvage treatment for
relapse or progression following RIC-SCT. An objec-
tive disease response (including CR, VGPR, and PR)
was achieved in 27 patients (73%). Lenalidomide
treatment for relapse MM was reported by Minnema
et al. [33]. Lenalidomide alone or in combination
with dexamethasone resulted in a response rate of
87.5%. Importantly, some patients developed
aGVHD when lenalidomide was given as monother-
apy within months after SCT or DLI. These studies
are performed in patients with relapsed or PD; how-
ever, the role of new agents in combination with cell
therapies for residual disease after RIC-SCT has not
been explored yet.
In conclusion, partial T cell-depleted RIC-SCT
has the advantage of a low 1-year TRM of 10%,
limited severe GVHD, and sustained GVM reactivity.
This strategy opens the possibility for posttransplanta-
tion immunotherapy, alone or in combination with
new agents. Because of the low incidence of aGVHD
and cGVHD, the quality of life in these patients
remains good and consequently preemptive immuno-
therapy can be performed in a majority of patients.
Therefore, in the era of RIC-SCT for MM, post-
transplantation strategies have become more impor-
tant than before. We show that vaccination with
recipient-derived DC is feasible, safe, immunogenic,
and most importantly, does not induce GVHD. The
potential of this approach to induce GVM reactivity
is not yet fully exploited. Further studies on the
coinfusion of donor lymphocytes with recipient-de-
rived DC or MiHA-loaded donor-derived DC are
needed.
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